Here are the DEF 14A proxy statements from Acurx Pharmaceuticals, Inc. (ACXP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow ACXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACXP filings page.
Acurx Pharmaceuticals, Inc. (ACXP) is soliciting proxies for its 2026 virtual annual meeting to be held at 10:00 a.m. EST on October 16, 2026. Stockholders of record as of August 20, 2026, when 5,471,297 common shares were outstanding, may vote online, by phone, mail, or during the webcast.
Stockholders are asked to elect two Class II directors, David P. Luci and Jack H. Dean, to three‑year terms ending in 2029, and to ratify CohnReznick LLP as independent registered public accounting firm for 2026. The board recommends voting FOR both proposals. The board remains classified into three classes and includes a majority of Nasdaq‑defined independent directors.
The filing details beneficial ownership, with all directors and current executive officers as a group holding 350,608 shares (6.5%) as of August 15, 2026. It also presents 2025 executive compensation, including base salaries, cash and non‑cash bonuses, and stock option grants (some in lieu of cash bonuses), along with director retainers and committee fees and the status of the 2021 Equity Incentive Plan.